Results 111 to 120 of about 39,262 (226)

Relationship between bisphosphonate use and risks of recurrence and mortality among hormone receptor–positive and triple‐negative breast cancer patients

Cancer, Volume 132, Issue 16, 15 August 2026.
Abstract Background Bisphosphonates (BPs) are routinely used as an adjuvant therapy for breast cancer to reduce the risk of bone recurrences given their anti‐resorptive effects on bones and antitumor characteristics. However, there remains limited evidence regarding their utility across different subtypes. Methods In this population‐based cohort study,
Liuye Huang, Linda S. Cook, Mei‐Tzu C. Tang, David R. Doody, Ulrike Peters, Wei Sun, Jeroen R. Huyghe, Kathleen E. Malone, Christopher I. Li   +8 more
wiley   +1 more source

Amuc_1473 Links Gut Microbes to Skeletal Homeostasis and Counteracts Multifactorial Osteoporosis

Advanced Science, Volume 13, Issue 44, 7 August 2026.
Amuc_1473, a previously uncharacterized protein enriched in Akkermansia muciniphila‐derived extracellular vesicles, is identified as a gut–bone messenger that promotes osteogenesis and inhibits osteoclastogenesis by engaging transcriptional and translational regulators in bone cells.
Shan‐Shan Rao, Hai‐Jin Zeng, Zun Wang, Chun‐Gu Hong, Yi‐Juan Tan, Yan‐Xin Duan, Jing‐Yao Luo, Ming‐Jie Luo, Yi‐Wei Liu, Xin Wang, Yi Luo, Teng‐Fei Wan, Yong Zhou, Zheng‐Guang Wang, Guo‐Wen Hu, Hao Yin, Xin‐Yue Hu, Zhen‐Xing Wang, Ze‐Hui He, Si‐Yi Cheng, Wei Du, Zhe Guan, Hai‐Li Lang, Hong‐Ji Liu, Jia Cao, Peng Chen, Jiang‐Hua Liu, Hui Xie, Chun‐Yuan Chen   +28 more
wiley   +1 more source

Hormone replacement therapy and its association with LATE‐NC in older adults

Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION Limbic‐predominant age‐related transactive response DNA‐binding protein 43 (TDP‐43) encephalopathy neuropathological change (LATE‐NC) is a cause of dementia resembling Alzheimer's disease (AD). The 90+ Study found women using hormone replacement therapy (HRT) two to three decades before death had lower odds of LATE‐NC.
Yohana M. Kim, Katherine Colcord, S. Ahmad Sajjadi, Elizabeth J. Andrews, Julie A. Schneider, Claudia H. Kawas, Maria M. Corrada   +6 more
wiley   +1 more source

Case Report: Gastrointestinal cancer initially presenting as postmenopausal osteoporosis. [PDF]

Front Oncol
Li J, Liu T, Chen Y, Xu Y, Ma L, Cheng X, Yan F, Gong Y, Sun R.   +8 more
europepmc   +1 more source

Prescribing of Medication to Prevent Glucocorticoid Harms in Patients With Polymyalgia Rheumatica: A Cross‐Sectional Study and Two Emulated Target Trials in the Clinical Practice Research Datalink Aurum

Arthritis &Rheumatology, Volume 78, Issue 8, Page 1731-1740, August 2026.
Objective Polymyalgia rheumatica (PMR) is a common indication for long‐term glucocorticoid (GC) treatment. Bone‐protective and gastroprotective medications are recommended for those at high risk of adverse events from GCs, but no trials have evaluated their effectiveness in PMR.
Helen Twohig, David Jenkinson, James Bailey, Samantha Hider, Ian C. Scott, Sara Muller   +5 more
wiley   +1 more source

Comprehensive profiling of gut microbiota in postmenopausal osteoporosis. [PDF]

Turk J Med Sci
Ertürk Çelik G, Yildiz S, Aksoy Bektaş M, Engin Üstün Y.   +3 more
europepmc   +1 more source

Mind the gap: Adherence to denosumab dosing and cessation guidelines in Australian residential aged care

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2819-2827, August 2026.
This original research used medication administration data to explore adherence to treatment guidelines for the most common osteoporosis medications in long‐term residential aged care (RAC) in Australia. The paper highlights gaps in adherence to treatment guidelines that must be addressed to improve outcomes of older adults living in RAC.
Marea O'Donnell, Johanna I. Westbrook, Bayzidur Rahman, Isabelle Meulenbroeks, Nasir Wabe, Ian D. Cameron, Mark Morgan, Magdalena Z. Raban   +7 more
wiley   +1 more source

Ubiquitin-proteasome system regulation of bone remodeling in postmenopausal osteoporosis. [PDF]

Front Cell Dev Biol
Chen X, Zhao T, Zhou H, Zeng Q, Xu H, Dai Y, Yan M.   +6 more
europepmc   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 334-344, August 2026.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu, Renn‐Chia Lin, Ing‐Lin Chang, Shau‐Huai Fu, Meng‐Ying Tsai, Shun‐Fa Yang   +5 more
wiley   +1 more source

A Cross-Tissue Multiomics Analysis Reveals the Protective Role of TGFBR3 in Postmenopausal Osteoporosis. [PDF]

Int J Genomics
Liu Y, Xie C, Yang K, Liu Z, Liu R, Hou X, Xing L, Gao J, Lian Q, Hu Y, Wang Y, Zhang L, Tian F.   +12 more
europepmc   +1 more source